05/20/2026
【Asia Pacific Biopharma Daily News Summary｜May 20, 2026】
APAC BioPharma on May 20, 2026 is being shaped by major neurodegenerative disease licensing deals, regulatory pricing reform in South Korea, and the commercialization of regenerative medicine.
In South Korea, and signed a potential $4.7 billion licensing agreement for AR-1001, including a $60 million upfront payment, making it one of the largest Alzheimer’s deals ever involving a Korean biotech company. At the same time, the Korean government announced a major generic drug pricing overhaul, reducing reimbursement calculations from 53.55% to 45% in an effort to redirect incentives toward high-R&D and essential medicine developers. Earnings across the sector also continue to diverge sharply: Samsung Biologics reported a 35% increase in Q1 operating profit, while Celltrion Global posted 115% growth, even as many mid-sized biotech companies faced declining profitability.
In Japan, Samsung Bioepis officially launched its Stelara biosimilar “SB17” through following inclusion in the national reimbursement system, expanding patient access for plaque psoriasis and psoriatic arthritis treatment. Meanwhile, Sumitomo Corporation Pharma’s iPS cell-derived Parkinson’s therapy “Amchepry” officially entered Japan’s NHI pricing list, becoming the world’s first commercialized medical product derived from induced pluripotent stem cells. Japan’s Ministry of Health, Labour and Welfare also added the country’s first biosimilars for Xolair, Ranmark, and Simponi into the reimbursement system, accelerating broader biosimilar adoption.
In China, entered a global clinical collaboration with MSD GCC to evaluate its CLDN18.2-targeting ADC ATG-022 in combination with KEYTRUDA® for gastric and gastroesophageal junction cancers. also emphasized its expanding “NewCo” strategy, focusing on overseas entity creation and global asset development to reduce exposure to domestic pricing and regulatory pressure.
In India, the pharmacy sector remains divided over nationwide protest actions targeting online pharmacies and aggressive discounting models, although several major pharmacist associations chose to remain open to ensure uninterrupted patient access. also reported strong FY26 earnings, with revenue up 14% and net profit surging 50% year over year, reinforcing the resilience of India’s injectables and CDMO sector.
In Australia, released new data for International Clinical Trials Day showing that nearly 50% of reviewed studies are now First-in-Human or Phase 1 trials, further reinforcing Australia’s role as a leading global hub for early-stage clinical development.
Taken together, APAC biopharma is increasingly moving beyond its historical role as a regional manufacturing base and becoming a global driver of innovation across Alzheimer’s disease, regenerative medicine, ADCs, and early-stage clinical development.
Which development do you think best represents the next phase of APAC biotech competitiveness?
